Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: J Immunol. 2017 Oct 9;199(10):3437–3452. doi: 10.4049/jimmunol.1700953

Figure 3. Analysis of clonotypic diversity in the Gag293-specific repertoire.

Figure 3

(A) Diversity of the TRAV24 (left) and TRBV2 (right) clonotype datasets was evaluated by the number of unique CDR3 amino acid sequences (clonotype AA) obtained per 100 cloned nucleotide sequences. Clonotypic diversity was compared between ADVAX recipients (week 10, red, TRAV24 n=4, TRBV2 n=4; week 38, light blue, TRAV24 n=2, TRBV2 n=3), HIV Controllers (HIC, dark blue, n=8), and treated patients (HAART, green, n=8). Significant differences (P < 0.05) obtained with the Mann-Whitney U test are reported.

(B) J and D gene usage in Gag293-specific clonotypes: Frequencies of TRAJ genes (top row), TRBJ genes (middle row), and TRBD genes (bottom row) in Gag293-specific TRAV24 or TRBV2 sequences were analyzed in the ADVAX, HIC, and HAART groups. TRAJ, TRBJ and TRBD gene families that predominate in in vaccinees (>8%) are depicted in colours, while all other genes families are shown in grey. Number of sequences analyzed: ADVAX TRA: 473; HIC TRA: 584; HAART TRA: 496; ADVAX TRB: 723; HIC TRB: 716; HAART TRB: 566.